What it said it expected, against what it reported
No target with a reported result yet
The numbers ABBV said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from
| Target | What the company said | Reported | Result |
|---|---|---|---|
| Diluted EPS (company-defined) Fiscal 2026 |
Given $14.37 to $14.57 release 2026-02-04
Lowered $14.08 to $14.28 release 2026-04-29
Lowered $13.87 to $14.07 release 2026-07-31
Narrowed $13.95 to $13.99 release 2026-10-30
|
– | No standard number |
The company's wordsProvides 2026 Adjusted Diluted EPS Guidance Range of $14.37 to $14.57; release 2026-02-04 AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.96 - $14.16 to $14.08 - $14.28, which includes an unfavorable impact of $0.41 per share related to acquired IPR&D and milestones expense incurred year- to-date through the first quarter 2026. release 2026-04-29 Updates 2026 Adjusted Diluted EPS Guidance Range from $13.91 - $14.11 to $13.87 - $14.07; release 2026-07-31 AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year- to-date through the third quarter 2026. release 2026-10-30 | |||
| Diluted EPS (company-defined) Fiscal 2025 (ended 2025-12-31) |
Given $12.12 to $12.32 release 2025-01-31
Lowered $12.09 to $12.29 release 2025-04-25
Lowered $11.88 to $12.08 release 2025-07-31
Lowered $10.61 to $10.65 release 2025-10-31
|
– | No standard number |
The company's wordsProvides 2025 Adjusted Diluted EPS Guidance Range of $12.12 to $12.32; release 2025-01-31 AbbVie is raising its adjusted diluted EPS guidance for the full year 2025 from $11.99 - $12.19 to $12.09 - $12.29, which includes an unfavorable impact of $0.13 per share related to acquired IPR&D and milestones expense incurred year- to-date through the first quarter 2025. release 2025-04-25 AbbVie is raising its adjusted diluted EPS guidance for the full year 2025 from $11.67 - $11.87 to $11.88 - $12.08, which includes an unfavorable impact of $0.55 per share related to acquired IPR&D and milestones expense incurred year- to-date through the second quarter 2025. release 2025-07-31 AbbVie is raising its adjusted diluted EPS guidance for the full year 2025 from $10.38 - $10.58 to $10.61 - $10.65, which includes an unfavorable impact of $2.05 per share related to acquired IPR&D and milestones expense incurred year- to-date through the third quarter 2025. release 2025-10-31 | |||
| Diluted EPS (company-defined) Fiscal 2024 (ended 2024-12-31) |
Given $11.05 to $11.25 release 2024-02-02
Raised $11.13 to $11.33 release 2024-04-26
Lowered $10.71 to $10.91 release 2024-07-25
Raised $10.90 to $10.94 release 2024-10-30
|
– | No standard number |
The company's wordsProvides 2024 Adjusted Diluted EPS Guidance Range of $11.05 to $11.25; release 2024-02-02 AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.97 - $11.17 to $11.13 - $11.33, which includes an unfavorable impact of $0.08 per share related to acquired IPR&D and milestones expense incurred during the first quarter 2024. release 2024-04-26 AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.61 - $10.81 to $10.71 - $10.91, which includes an unfavorable impact of $0.60 per share related to acquired IPR&D and milestones expense incurred year- to-date through the second quarter 2024. release 2024-07-25 AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.67 - $10.87 to $10.90 - $10.94, which includes an unfavorable impact of $0.64 per share related to acquired IPR&D and milestones expense incurred year- to-date through the third quarter 2024. release 2024-10-30 | |||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (24 releases since 2024-01-05), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.